CMS Issues Coverage Guidance on GLP-1 Anti-Obesity Drugs: Implications for Health Plans Posted on April 5, 2024 CMS Issued Coverage Guidance on GLP-1 Anti-Obesity Drugs Requiring Considerations for Health Plans GLP-1s (glucagon-like peptide 1 agonist) came up in the news again after the Centers for Medicare and Medicaid Services (CMS) issued coverage guidance on GLP-1 anti-obesity drugs with expanded indications on March 20, 2024.* Since the inception of Medicare Part D, drugs used for weight loss have been excluded from basic coverage
Lipo C Injection, 15 / 50 / 50 / 5 mg/mL 3,500/Box Lipo-C Injection is a sterile intramuscular formulation that combines four lipotropic and metabolic cofactors-methionine, choline chloride, L-carnitine, and dexpanthenol-at 15 mg/mL, 50 mg/mL, 50 mg/mL, and 5 mg/mL, respectively, in water for injection
Jamie DePolo: That's fascinating
For me, it wasnt painful, but I was aware of itlike a mild sensation at the placement spot